E-cigarettes can compromise the immune system in the lungs
Scientists from John Hopkins University in Maryland, exposed mice to e-cigarette vapour twice a day for two weeks at a level designed to proportionally mimic the amount a person who regularly used e-cigarettes would inhale. They then administered some of the mice with an influenza virus and others with the streptococcus pneumoniae bacteria, which is responsible for pneumonia, sinusitis and other illnesses.
Compared to a control group, the mice that had been exposed to the vapour were less able to fight off illness, and some died. Professor Shyam Biswal, senior author of the study, said the findings suggested “e-cigarettes are not neutral in terms of the effects on the lungs” and said that studies should now be carried out on people, particularly those with common lung problems such as chronic obstructive pulmonary disease (COPD), which often affects smokers and ex-smokers – the main users of e-cigarettes.
Debate over the public health impact of e-cigarettes remains fierce. They have been shown to be highly effective in helping smokers to quit, and there is a broad consensus that despite some uncertainty over their health impact, they are less harmful than tobacco cigarettes.
However, this very uncertainty means other health experts remain concerned e-cigarettes could pose risks to future generations, particularly given evidence from some countries that they are becoming more popular among young people who have never smoked.
There are also concerns that more tobacco companies are increasingly entering the e-cigarette market, and so, World Health Organisation has recommended they be banned in indoor public spaces – a measure the Department of Health in England has ruled out, but which is being considered by the Welsh government.
The new study, published in the PLOS ONE journal, also found e-cigarettes contain DNA-damaging toxins known as free radicals – but at levels about 1 per cent of that found in a cigarette. “We have observed that [e-cigarettes] increase the susceptibility to respiratory infections in mouse models,” said Professor Biswal. “This warrants further study in susceptible individuals, such as COPD patients who have switched from cigarettes to e-cigarettes or to new users of e-cigarettes who may never have used cigarettes.”
However, Professor John Britton, director of the UK Centre for Tobacco Control Studies said the most important point was that harm to the lungs was less from e-cigarettes than from tobacco.
“The lung is an exquisitely delicate organ and therefore nobody with any common sense would believe that inhaling heated vapour many times a day would be harmless,” he said. “What matters here is not a comparison of the effects of e-cigarette vapour compared with nothing, but the effects compared with those of tobacco smoke.
“Harm to the lungs will be less with electronic cigarettes than tobacco cigarettes, and any smoker who cannot quit using nicotine, and doesn't find medicinal products effective, would be well advised to try an electronic cigarette.”